Juq-934 Official

| Property | Value | |----------|-------| | | 3‑[(4‑fluorophenyl)amino]‑2‑[(1‑methyl‑1H‑imidazol‑5‑yl)methyl]‑5‑(trifluoromethyl)‑1,4‑dihydro‑pyridine‑6‑carboxamide | | Synonyms | JUQ‑934; 4‑F‑BETA‑3; PTC‑938 | | Molecular formula | C₁₈H₁₈F₄N₅O | | Molecular weight | 387.33 g·mol⁻¹ | | SMILES | CC1=CN(C=N1)CCc2cnc(Nc3ccc(F)cc3)nc2C(F)(F)F | | InChIKey | XJXKZVQWZKYJGT-UHFFFAOYSA-N | | Physical state | White crystalline solid; soluble in DMSO, moderately soluble in 0.5 % methylcellulose (pH 7.4) | | pKa (predicted) | 7.6 (basic imidazole) | | LogP (XlogP3-AA) | 3.1 (moderately lipophilic) |

– Order a JUQ‑934 server from any major OEM (e.g., Dell, HPE, Supermicro). The unit ships pre‑installed with a modified Ubuntu 24.04 LTS image. JUQ-934

“When the sky was still young, the Luminarchs set a stone at the heart of every star. Each stone sang a note, and together they wove the fabric of reality. If one stone falls, the song falters, and the night grows cold.” | Property | Value | |----------|-------| | |

BET proteins (BRD2, BRD3, BRD4, and BRDT) recognize acetyl‑lysine residues on histone tails and act as “readers” of epigenetic marks, recruiting transcriptional complexes that drive expression of oncogenes (e.g., MYC , BCL‑2 ). Inhibition of BET bromodomains has been validated in pre‑clinical models of hematologic malignancies, solid tumours, and inflammatory diseases. However, first‑generation BET inhibitors (e.g., JQ‑1, OTX‑015) suffer from dose‑limiting toxicities (thrombocytopenia, gastrointestinal upset) and a relatively narrow therapeutic window. Each stone sang a note, and together they

| Cell line | Assay | EC₅₀ (nM) | Observed effect | |-----------|-------|-----------|-----------------| | MV4‑11 (AML) | c‑Myc down‑regulation (Western blot) | 35 ± 5 | > 80 % reduction after 24 h | | NCI‑H2228 (EML4‑ALK NSCLC) | Cell viability (CellTiter‑Glo) | 62 ± 7 | GI₅₀ ≈ 80 nM | | THP‑1 (monocytic) | Cytokine suppression (IL‑6 ELISA) | 120 ± 15 | 45 % decrease after LPS challenge | | Human platelets | Viability (LDH release) | > 10 µM | No measurable toxicity up to 10 µM |

The synthetic route to JUQ‑934 is concise (four steps) and amenable to scale‑up. A representative laboratory synthesis (patent Example 7) is summarized below:

– The existence of a pre‑human, galaxy‑wide synchronization device forces us to reconsider the narrative of civilization’s origin. Were the Luminarchs merely a forgotten species, or were they architects of the very laws we now take for granted?